Apr 03, 2019 4:05pm EDT Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance
Mar 22, 2019 3:30pm EDT Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
Mar 12, 2019 7:00am EDT Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
Mar 04, 2019 7:00am EST Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
Feb 25, 2019 4:05pm EST Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development
Feb 20, 2019 7:00am EST Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine
Feb 19, 2019 7:00am EST Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
Feb 14, 2019 7:00am EST Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019
Feb 11, 2019 7:00am EST Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville